A phase II, single-arm study of the anti-?5?1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples